Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects. It is likely that a small molecule could be found with lithium-like efficacy but without toxicity through target-based drug discovery; however, lithium's therapeutic target remains equivocal. Inositol monophosphatase is a possible target but no bioavailable inhibitors exist. Here we report that the antioxidant ebselen inhibits inositol monophosphatase and induces lithium-like effects on mouse behaviour, which are reversed with inositol, consistent with a mechanism involving inhibition of inositol recycling.
accumulates and inositol is depleted 7 . Given that in neurons regeneration of phosphatidylinositol 4,5-bisphosphate requires recycling of inositol from Ins1P, lithium dampens signalling in cells with overactive signalling through pathways using a G-proteincoupled receptor linked to phospholipase C 7 .
IMPase remains a potential therapeutic target for bipolar disorder, but its validation requires small molecule inhibitors. However, little progress has been made in regard to inhibitors since a large effort by Merck yielded a potent (IC 50 300 nM) antagonist (L-690,330) but neither it nor its esterified prodrug (L-690,488) was bioavailable 14, 15 . We now report that ebselen inhibits IMPase and acts as a lithium mimetic in mouse models of bipolar disorder.
Results

Repurposing reveals ebselen as an inhibitor of IMPase
To identify an inhibitor of IMPase, we expressed human IMPase in bacteria and used it in an assay to screen the NIH Clinical Collection provided through the National Institutes of Health Molecular Libraries Roadmap Initiative 16 . Compounds in this collection have a history of use in human clinical trials, are drug-like with known safety profiles and may even be appropriate for direct human use in new disease areas (www.nihclinicalcollection.com). A primary screen at 100 μM of each drug in the collection identified ebselen (Fig. 1a) as an inhibitor of IMPase, and we characterized it further with a full concentration-response curve (Fig. 1b) . The potency of ebselen against IMPase (IC 50 1.5 μM) compared favourably to that of the known but poorly bioavailable inhibitor L-690,330 14 (IC 50 0.3 μM) and was greater than that of lithium (IC 50 0.8 mM; Fig. 1b) . Importantly, the greater potency of ebselen for IMPase (Fig. 1b) compared to glycogen synthase kinase 3ß (Fig. 1c) demonstrates selectivity, making ebselen of diagnostic use in determining the therapeutic potential of IMPase inhibition.
Ebselen inhibition is irreversible and covalent
As increasing concentrations of ebselen decreased V max with little effect on K m (Fig. 1d,e) the inhibition is not competitive 17 . Inhibition of IMPase by ebselen was not fully relieved by dilution (20 μM to 0.2 μM ebselen; Fig. 1f ) even after a time course for recovery extending to 25 h (Fig. 1g) , thus indicating that inhibition is, for practical purposes, irreversible. (A reversible inhibitor would lose potency upon dilution due to mass action promoting dissociation 17 .) As irreversible inhibition often arises from covalent binding, we looked for direct evidence of ebselen binding to IMPase. Mass spectrometry revealed that a mixture of IMPase and ebselen formed complexes heavier than pure IMPase dimer by the mass of one or two ebselen molecules under both denaturing and non-denaturing conditions (Fig. 1h) , supporting covalent binding and 1:1 stoichiometry per monomer. In contrast, a mixture of IMPase and the reversible inhibitor L-690,330 14 formed heavier complexes under nondenaturing conditions, but not under denaturing conditions (Fig. 1h ).
Ebselen contains selenium (Fig. 1a) , which can form a selenylsulfide (-Se-S-) bond 18, 19 . For bovine IMPase, alkylation of cysteine 218 with the non-selective agent Nethylmaleimide inhibited activity 20 . In bovine IMPase, cysteine 218 is near the active site residue aspartate 220, which is required for magnesium ion coordination and catalysis 20 . The position of this cysteine is conserved in both the mouse and human isoforms based on its crystal structure 21 . To test the importance of this cysteine in mediating ebselen inhibition, we constructed a human IMPase with a cysteine to alanine mutation (C218A). The C128A mutant was indeed less sensitive to ebselen inhibition, based on the increase in IC 50 for ebselen (Fig. 1i ) and a smaller decrease in V max (Fig. 1j,k) . Furthermore, an analogue ebselen in which the selenium is substituted with sulphur (ebsulfur; Fig. 1a ) weakly inhibited IMPase (Fig. 1l) , whereas a selenium-containing compound with similar electrophilic reactivity (dibenzyldiselenide; Fig. 1a ) had no inhibitory effect (Fig. 1l ). These data demonstrate that inhibition of IMPase by ebselen requires not just the presence of an electrophilic selenium atom but also an appropriate chemical scaffold. Unlike the case for most other proteins when covalently linked to ebselen 18, 19, 22 , inactivation of IMPase was not reversed by post-incubation with the sulfhydryl reducing agents glutathione and dithiothreitol (Fig. 1m) . Pre-incubation of ebselen with the reducing agents did, however, reduce inhibition (Fig. 1n) as described in detail below.
Ebselen is pharmacologically active in the brain
To determine whether ebselen can cross the blood-brain barrier and thus be pharmacologically active in mouse brain, as reported for rat 23 , we exploited the irreversible inhibition property of ebselen in an ex vivo method based on IMPase activity in brain homogenate (Fig. 2a) . As the initial experiments that identified ebselen as an inhibitor used recombinant human IMPase (Fig. 1b) , we first needed to ensure that recombinant mouse IMPase was enzymatically active. Recombinant mouse IMPase was inhibited by lithium and L-690, 330 and ebselen (Fig. 2b) . Having validated that ebselen inhibited the mouse form of IMPase, we demonstrated that in homogenates of mouse brain, IMPase activity was detectable and inhibited by lithium, L-690,330 and ebselen (Fig. 2c) . In an ex vivo experiment, IMPase activity was measured in brain homogenates prepared at various times after intraperitoneal injection of ebselen (Fig. 2a) 24 . Over time, IMPase inhibition developed and then returned to control levels ( Fig. 2d,e) . Therefore, systemic administration of ebselen inhibits IMPase in mouse brain in whole animals.
That IMPase inhibition by ebselen was detected in the ex vivo experiments (Fig. 2d,e) is revealing in regard to the likely chemical form of ebselen in intact cells in vivo, as its selenium atom can exist in higher or lower oxidation states, and these have different reactivities 18, 19 . Incubation of ebselen with reduced glutathione forms ebselen-glutathione selenenylsulphide, whereas incubation with dithiothreitol reduces ebselen to its selenol and diselenide (Fig. 1a,l) 18, 19 . When we pre-incubated ebselen with these reducing agents the reduced forms of ebselen (confirmed by mass spectrometry) were weaker inhibitors of IMPase (Fig. 1n) , likely because they are less reactive with cysteines 18 . Therefore, to obtain inhibition of IMPase with ebselen in vivo a fraction of ebselen must exist in a nonconjugated free form in the oxidation state shown in Fig. 1a , despite an intracellular environment with millimolar concentrations of reduced glutathione 25 .
Ebselen alters the function of the central nervous system
To determine whether ebselen was affecting the function of the central nervous system, we investigated the effect of ebselen on the responses mediated by the serotonergic 5-HT 2 receptor 26 . In humans, lithium reduces phosphoinositide cycle-coupled 5-HT 2 receptor function 27 , and this may be linked to lithium's antidepressant action. Lithium also reduces 5-HT 2 receptor function in mouse as modelled by a 5-HT 2 agonist-evoked head-twitch response 28 . This is mediated by the prefrontal cortex 29 , which is believed to be the target of lithium in the treatment of bipolar disorder 30 . Ebselen decreased 5-HT 2 agonist-induced head twitches in a dose-dependent manner (Fig. 3a) , and this was associated with decreased expression of Arc mRNA (a molecular marker of neural activity 26 ) in the prefrontal cortex ( Fig. 3b ) and cingulate cortex (Fig. 3c) . Thus, ebselen attenuates a cortically mediated 5-HT 2 receptor response that is linked to phosphoinositide turnover, as would be predicted for an inhibitor of IMPase.
Ebselen exhibits lithium-like effects on behaviour
Rodent behaviours are used to model bipolar disorder, and typically focus on either the manic or the depressive pole 31 . The 'learned helplessness' aspect of depression is often modelled with the forced swim test. In this model, ebselen has recently been shown to exhibit anti-depressant action 32 . Given these findings, we investigated the effect of ebselen in lithium-sensitive mouse models of mania 33 . In the open field test (Fig. 3d) , rearing was decreased by ebselen over time and then returned to baseline (Fig. 3e) , a time course that paralleled that for IMPase inhibition in the ex vivo assay (Fig. 2e) , as well as plasma ebselen concentrations in humans after oral administration 34 . Rearing is an exploratory behaviour that correlates with impulsivity 33 , which in turn correlates with suicidal thoughts and actions 35 . Mania has also been modelled by amphetamine-induced hyperactivity (Fig.  3f) 33, 36 . Similarly to lithium 37 , ebselen reduced amphetamine-induced hyperactivity in a manner that depended on both the dose of amphetamine and the dose of ebselen (Fig. 3g) , as is the case for lithium 37 . Baseline mobility was not significantly reduced (one-tailed, paired t-tests: amphetamine 2 mg/kg and ebselen 5 mg/kg, p=0.24; amphetamine 4 mg/kg and ebselen 5 mg/kg, p=0.08).
Ebselen acts through inositol depletion
Finally, if ebselen were mimicking lithium by inhibition of IMPase (and therefore inositol depletion), then one would expect ebselen's effects to be circumvented by administration of exogenous inositol. This reversal is diagnostic of the 'inositol depletion hypothesis' if the addition of inositol re-establishes normal phosphatidylinositol 4,5-bisphosphate signalling 7, 8, 38 . We injected inositol intracerebroventricularly (Fig. 4a) , and this reversed the effects of ebselen in models of both rearing (Fig. 4b ) and amphetamine-induced mobility (Fig. 4c) . Furthermore, mice injected intraperitoneally with ebselen, showed a decrease in brain levels of inositol 1 h after administration (Fig. 4d,e) providing direct evidence for inositol depletion. Combined, these results are consistent with the known ability of inositol to reverse the behavioural effects of lithium 8, 9, 38 and support the inositol depletion hypothesis 7 .
Discussion
Despite 60 years of use since its discovery as a mood stabilizer 4 , lithium remains the gold standard for the treatment of bipolar disorder 1 . Although combination therapy with an antidepressant is used to treat bipolar disorder, there is a risk of precipitating mania 39 . Uniquely, lithium is the only drug reported to reduce suicidal thoughts and behaviour 2 . Lithium is less than ideal, however, due to its undesirable side effects and toxicity. Therefore, there is a crucial need for drugs that are safe and efficacious for the treatment of bipolar disorder. Currently, drugs fail clinical trials for primarily safety or efficacy 40 . Ebselen, is known to be clinically safe 34, 41 and hence its efficacy should be tested.
Ebselen exhibits lithium-like actions at many levels including enzymatic, inositol recycling and animal behaviour making it the best lithium mimetic reported to date 5 . Additionally, ebelen is bioavailable, blood-brain barrier permeant and safer than lithium based on cellular toxicity 42 and Phase 1-3 clinical trials 34, 41 . Ebselen exhibits a polypharmacology profile (http://mli.nih.gov/mli/mlp-probes/) that would be predicted to be beneficial in its role as a lithium mimetic because it directly inhibits the putative therapeutic targets of lithium including IMPase and protein kinase C 43 as well as being an antioxidant and inhibitor of cyclooxygenases that promotes neuronal survival 44 . Polypharmacology is much more common than previously appreciated 45 . Moreover, polypharmacology is now a desirable property 46, 47 , for example, antipsychotics hitting multiple targets were more efficacious than drugs that were selective 48 .
Inhibition of IMPase by ebselen is covalent and irreversible. Traditionally, covalent drugs have been disfavoured due to risks relating to immunogenicity 49 . However, covalent binding alone is not sufficient to cause problems 50 and many marketed drugs act covalently 49 , demonstrating that such risks are compound specific. Importantly, ebselen has a good safety profile in all animal and human experiments reported to date 34, 41 . Moreover, the irreversible action of ebelen on IMPase offers several advantages, as is that case for all irreversible drugs 49, 51, 52 . One is that an irreversible inhibition cannot be overcome by accumulation of substrate. Additionally, irreversible inhibition can interact with pharmacokinetic effects to prolong ebselen's duration of action and increase its selectivity for IMPase. After dosing, the decreasing concentration of ebselen will decrease its inhibition of all its reversible secondary targets. In contrast, IMPase will remain inhibited until new enzyme is synthesized. Such a scenario is known to be the case for many marketed drugs that are covalent and irreversible inhibitors including the well known drugs aspirin, clopidogrel and omeprazole 49 .
There is an increasingly urgent need for new drugs for the treatment of mental illness, especially given that many large pharmaceutical companies have pulled out of these areas due to high costs and failure rates 39, 53 prompting speculation as to where new drugs will come from for treating disorders of the central nervous system 54, 55 . Although there is no single solution, repurposing of drugs from their original use to a new use is being strongly promoted by government initiatives such as that announced by the NIH 16, 56, 57 . Given that ebselen has been in clinical trials 34, 41 , ebselen offers all the promise of drug repurposing 58 .
Methods
Recombinant Inositol Monophosphatase
Murine MmImpa1 and human HsImpa1 were amplified from cDNA clones (IMAGE clones 6413389 and 3682657, respectively; Source Bioscience, Cambridge, UK). Cloning and protein expression were carried out as reported 21, 59 . Semi-purified recombinant protein was obtained by heating lysed-cell supernatant (68°C, 1 h) and centrifugation (30,000 g, 30 min, 4°C).
Cysteine 218 to Alanine Mutation in IMPase
Site directed mutagenesis of cysteine 218 was carried out using the Stratagene QuickChange kit. Protein was expressed as before, but without sorbitol and betaine.
IMPase Activity
Phosphate hydrolyzed from Ins1P was detected using the malachite green assay. For the in vitro assays, recombinant HsIMPase (10 ng/well) or MmIMPase (30 ng/well) was incubated (1 h, 37°C) with Ins1P (1mM) in 20 μL Tris buffer (50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl 2 , 150 mM KCl, 0.5 mg/mL BSA and 0.01% v/v Triton X pH 7.4). Absorbance was measured at 595 nm for samples and phosphate standards. For the ex vivo assays, brain homogenate (0.5 mg/mL) was incubated (37°C, 1 h) with Ins1P (0.1-2.4 mM) in the presence or absence of LiCl (30 mM) to determine IMPase-specific activity.
Chemical Library and Screening
The NIH Clinical Collection of 450 compounds was provided by the National Institute of Health 16 and purchased from BioFocus DPI. Compounds (100 μM) were screened at three concentrations of Ins1P. Initial hits were confirmed with concentration-inhibition curves spanning six orders of magnitude. Subsequent experiments used ebselen from Fisher Scientific. For compound screening, compound at 100 μM (in 0.2% v/v DMSO) was incubated with IMPase (10 min, room temperature) in buffer, before addition of Ins1P (1 mM) to a final volume of 20 μL and further incubated (37°C, 1 h). Phosphatase concentration was determined by the malachite green assay. LiCl and L-690,330 (Tocris) were used as positive controls.
Reduced Ebselen
Ebselen (250 μM) was treated with 0.25 M dithiothreitol (DTT) or 5 mM GSH; reduced ebselen (final concentration 50 μM) was incubated (1 h, room temperature) with HsIMPase before addition of Ins1P (0.1-3 mM) and further incubation (1 h, 37°C) . Enzyme activity was determined by the malachite green assay.
Testing for Reversibility of Drug Inhibition
HsIMPase (1 μg/well) was incubated with 20 μM drug for varying times before dilution to 10 ng/well, addition of Ins1P and further incubation (1 h, 37°C). Enzyme activity was determined by the malachite green assay.
Selenyl-Sulfur Reversibility
Conditions were as described above, except that 2 μL of reductant (50 mM DTT or 1 mM GSH) was added to each well, after incubation of IMPase with ebselen.
Mass Spectrometry
IMPase (100 μM) was desalted using a Bio-Spin 6 Column (Bio-Rad) in 15 mM ammonium acetate (pH 7.5) and incubated (room temperature, 15 min) with 10 mM MgCl 2 prior to nondenaturing electrospray ionization mass spectrometry analysis (Q-TOF micro, Micromass). Data were processed with MASSLYNX 4.0 (Waters). To investigate IMPase ligand binding, mass spectrometry was used as described 60 , but with an additional mild denaturing step. HsIMPase (100 μM) was incubated with 100 μM drug (10 min) then diluted (1:10) in 15 mM ammonium acetate buffer (pH 7.4) with 0.1% v/v formic acid. This solution was then subjected to mass spectroscopy.
Animals
All studies used 20-25 g 10-12 week old male C57Bl6 mice (Harlan Olac, UK). Mice were housed with 12 h light-dark cycles with free access to standard lab chow and water. Experiments were carried out in accordance with UK Home Office Animals (Scientific Procedures) Act (1986) and associated code of practice guidelines. Animals were dosed intraperitoneally (i.p.) at 10 μL/g, unless otherwise specified. Lithium was dosed i.p. at 67 μL/g.
Ex Vivo Mouse Brain Homogenate
Mice were injected with ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin) and left for varying amounts of time before euthanization by cervical dislocation, or by CO 2 followed by cervical dislocation. Brains were removed and frozen on dry ice immediately. One hemisphere was homogenized using a Precellys 24 bead mill homogenizer (Stretton) and diluted in Tris buffer (50 mM Tris HCl, 3 mM MgCl 2 , 150 mM KCl, 1 mM EGTA, 0.01% v/v Triton X pH 7.4) to a final concentration of 0.5 mg/mL.
Ex vivo Inositol Measurement by Nuclear Magnetic Resonance
Mice were euthanized by cervical dislocation 1 h after administration of ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin), then brains were extracted and frozen immediately on dry ice. Brains were weighed then homogenized using a Precellys 24 bead mill homogenizer (Stretton). Acetonitrile was added to homogenate (1:1 v/v) to precipitate protein, the sample was centrifuged (13,000×g, 10 min), and the supernatant was prepared for NMR by lyophilization and reconstitution in D 2 O with 0.008% w/v 3-(trimethylsilyl)propionic 2233d acid sodium salt (600 mg/mL).
Amphetamine-induced Hyperactivity
Mice were treated with ebselen or vehicle and immediately placed in Linton AM1053 X, Y, Z IR Activity Monitor (San Diego Instruments) for 1 h to habituate. Mice were then injected with D-amphetamine/saline and returned to the cage, and activity was monitored for an additional 1 h.
Rearing behavior
Mice were injected with ebselen (10 mg/kg) or vehicle (4% w/v hydroxypropyl ß-cyclodextrin) and left for varying amounts of time before being placed in the Linton AM1053 X, Y, Z IR Activity Monitor (San Diego Instruments) for 30 mins while their activity was monitored. Rearing was measured by counting the number of beam breaks in upper grid.
Intracerebroventricular Injection of Inositol
Inositol reversal experiments were performed as described 38 . With mice under isofluraneinduced general anaesthesia, a guide cannula was stereotaxically implanted to 1 mm above the injection site in the lateral ventricle, and held in place with dental cement (Aqualox). Mice were left to recover for 7 days before behavioural studies were carried out. Inositol (5 or 1 μL of a supersaturated solution ≥ 278 mM) or control (0.9% w/v NaCl) was injected intracerebroventicularly, then 24 h later amphetamine-induced hyperactivity was assessed as described above. Group means were compared with pre-planned t-tests, one-tailed or paired as appropriate.
DOI-induced Head Twitches
Mice were placed in an arena and left to acclimatize to the novel environment. After 1 h, they were injected with vehicle or ebselen (5 or 10 mg/kg) followed 1 h later by the nonselective 5HT 2A agonist 1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane (DOI, 2 mg/kg). Head twitches were recorded 5 min after agonist injection for 15 min. Mice were constantly monitored by a video camera, and behavioural recordings were analysed offline independently by two observers who were blind to the treatment.
In Situ Hybridization
For quantification of Arc mRNA, brains were removed 1 h after the last injection of drug or vehicle and snap frozen in isopentane cooled by dry ice. Brain tissue sections (12 μm) were cut in a cryostat (-21°C), thaw-mounted onto gelatine-subbed slides and stored (-80°C), then pretreated using standard methods. For in situ hybridisation, oligonucleotides complimentary to Arc mRNA were 3′-tail labelled with [ 35 S]dATP and applied to each section in hybridization buffer (1×10 −6 cpm/section). After overnight incubation at 37°C, sections were washed in buffer (3M NaCl and 300 mM citrate, pH 7) first at 55°C (3×20 min) then at room temperature (2×60 min). Sections were then allowed to dry overnight and exposed to Kodak Biomax MR film (Sigma-Aldrich) for 7 days at room temperature. Films were developed and analysed with a computerized image analysis system using densitometric software (MCID, Linton, UK).
Statistical Analyses
Means were compared with pre-planned t-tests (one-tailed or paired as appropriate) using GraphPad Prism software. All data are presented as mean ± standard error of the mean. in d) , and analyzed by a pre-planned one-way t-test between ebselen and control, n=4. All error bars represent standard error of the means.
